Bio-Rad Laboratories, Inc. (NYSE:BIO) is Southeastern Asset Management Inc. TN’s 8th Largest Position

Southeastern Asset Management Inc. TN lowered its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 308,469 shares of the medical research company’s stock after selling 9,867 shares during the quarter. Bio-Rad Laboratories makes up approximately 4.8% of Southeastern Asset Management Inc. TN’s holdings, making the stock its 8th biggest position. Southeastern Asset Management Inc. TN owned about 1.10% of Bio-Rad Laboratories worth $101,335,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Metis Global Partners LLC grew its stake in shares of Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock valued at $234,000 after acquiring an additional 30 shares during the period. Signaturefd LLC boosted its stake in Bio-Rad Laboratories by 13.2% in the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock worth $87,000 after purchasing an additional 31 shares during the period. UMB Bank n.a. boosted its stake in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Thrivent Financial for Lutherans boosted its stake in Bio-Rad Laboratories by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock worth $1,488,000 after purchasing an additional 32 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in Bio-Rad Laboratories by 3.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BIO has been the topic of several recent research reports. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company decreased their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada decreased their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Citigroup decreased their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Finally, UBS Group decreased their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average target price of $327.40.

Bio-Rad Laboratories Price Performance

BIO opened at $242.94 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The business’s fifty day simple moving average is $243.51 and its 200-day simple moving average is $299.31. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of -3.74 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The company had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same quarter last year, the company earned $2.30 earnings per share. The firm’s revenue for the quarter was down 4.2% compared to the same quarter last year. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.